Chapter 1: The science and the scan
"Boring, But Necessary"
- Hybrid Imaging System
- Anatomic & Functional Exam
- The Machine
- “Whole Body” vs. “Skull Base to Mid-Thigh”
- Three Sets of Images
Produced
- Glucose Analog
- Malignancy & Glucose Metabolism
- Mechanisms for Increased Intracellular Glucose
- Why 18F-FDG Works
- Whole Body Assessment
- The “You’re Kidding Me!” Effect
- Post-Therapeutic Scar vs. Active Malignancy
- Detecting Malignancy
- Staging Malignancy
- Assess Response to Therapy
- Detecting Recurrence
- Not All Cancer is FDG-Avid
- Normal FDG-Uptake vs. Pathologic Uptake
- Technical Limitations
- Poor Patient Preparation
- Misregistration
- Brown Fat Activation
- SUV Problems
- Fields of View Discrepancy
- PET/CT Artifacts
- Timing of Exam After Therapy
- CT Images
- Non-Attenuation Corrected Images
- Attenuation Corrected Images
- Maximum Intensity Projection (MIP)
- Fusion of Images
- All Images Viewed in 3 Planes
7. Contrast Media: Oral & I.V.
- Who Gets Oral Contrast?
- Who Gets IV Contrast?
- Oral Contrast “Cocktail” Recipe
8. What the Patient Should Expect
- Documenting Height & Weight
- Private Resting Room
- Drinking PO Contrast
- FDG Injection
- Delay Between Injection & Scan
9. Safety Concerns with PET/CT Imaging
- Radiation Exposure to Patient
- Radiation Exposure to Patient’s Contacts
- Patient Contact with Pregnant Women
- Breastfeeding
Chapter 2: PET/CT Problems Which Limit Interpretation
"Something just doesn't seem right here"
- Optimizing Glucose & Insulin Levels
- Fasting Prior to Exam
- Diabetic Patients
- Low Carbohydrate Diet
- Hydration
- Strenuous Exercise
- Voiding Prior to Exam
- Patient Instruction Sheet
- Definition
- Distribution / Appearance
- Don’t Miss the Hidden Nod
- Reporting Language
- Prevention
3. Timing of PET/CT Exam After Therapy
- “Rule of 3”
- Chemotherapy: 1 month
- Surgery: 2 months
- Radiation: 3 months
- Etiology: Hybrid Imaging
- Patient Movement
- Respiratory Motion
- Breathing Techniques
- Bowel Peristalsis
- False Positives
- False Negatives
- Reporting Language
- Beam Hardening
- Diaphragmatic Mismatch
- Linear Hand Motion
- Attenuation Correction
- Differing Fields of View
- Poor Patient Preparation
- FDG Extravasation
- Extensive Brown Fat
- Metformin-Induced Bowel Uptake
- Marked Reactive Marrow Uptake
- Extensive Tumor Uptake in
- Different Types of SUV Measurements
- Factors that Influence SUV Measurements
- What SUV Number Indicates Malignancy?
- What Percent Change in SUV on a Follow Up Exam is Significant?
- How to Compare Exams With Very Different Background Metabolic Activities?
Chapter 3: The Standardized Uptake Value (SUV)
"The good, the bad & the ugly"
1. What is the SUV & Why Used?
- Quantitative vs. Qualitative Assessment
- Unitless Measurement
- Formula
- SUV = ?
- Patient Preparation
- Time Between FDG Injection & Scan
- Partial Volume Effects
- Extravasation
- Patient Weight
- Size & Position of ROI
- Attenuation Correction Artifacts
- Consensus?
- Body Weight
- Lean Body Mass
- Ideal Body Weight
- Body Surface Area
- Maximum vs. Mean
- Average SUV’s by Organ
4. Interpreting the SUV: Threshold Values, “Oncologic Plausibility” & Relative Uptake
- Precise Threshold Values?
- “Oncologic Plausibility”
- Relative Uptake
- Assessing Nodes in Lymphoma Cases
- Assessing Nodes in Non-Lymphoma Cases
- Potential Lesions in Solid Organs
- Pulmonary Nodules
5. What % Change in SUV on a Follow Up Exam is Clinically Significant?
- The Problem
- Current Recommendations
6. How to Compare Sequential Exams With Very Different Background Activities?
- Differing Background Metabolic Activities
- When Qualitative Assessment is Required
- Reporting Language
7. Should We Just Abandon the SUV?
- Pros & Cons
- “Qualitative” Definitions
- Mild
- Moderate
- Intense
- Final Recommendations
Chapter 4: Our Systematic Approach to Reading a PET/CT
"Eat your vegetables"
1. Reading Station & Reading Software
- Reading Station
- Monitor Set-Up
- PET/CT Reading Software
- Hanging Protocol
- Reading in Context (“Oncologic Plausibility”)
- Measure Size on CT, Not on PET Images
- Abnormality Seen Only on First PET Image
- Assess the Patient’s Main Pathology Last
- Beware the Ureter
3. Excellent Views: The MIP, Coronal & Sagittal Images
- 3-D Rotating MIP & Coronal “Quick MIP”
- Coronal PET
- Sagittal PET
4. Written Annotations While Reading
- Numbers, Numbers & More Numbers
- Size & SUV Annotation System
- Sample Annotation Sheet
- Goals of Reporting
- Lawyers, Lawyers & Lawyers
- Sample PET/CT Report
- Negative Exam
- Positive Exam
- Patient Questionnaire
- Technologist’s Data Sheet
- Huge Exam: Requires Systematic Approach
- Our “12-Step Reading System”
- “The Read” in Action: Sample Case (Video)
- Annotations for Sample Case
- Final Report for Sample Case
Chapter 5: Normal Physiologic Distribution of FDG
"The essentials"
- To Locate Cancer, First Eliminate:
- Normal FDG-Avid “Structures”
- Benign FDG-Avid “Findings”
Chapter 6: Benign FDG-Avid "Findings" & Common Diagnostic Challenges
"Separating the Expert from the Not-So-Expert"
3. Chest
- Inflammatory Lymph Nodes
- Thymic Rebound
- Pleura: Talc Pleurodesis vs. Malignancy vs. Inflammation
-
Radiation-Induced Lung Disease
- Radiation Pneumonitis
- Radiation Fibrosis
- "Post-Therapeutic Inflammatory Changes" / Scarring of the Lung
- Atelectasis / Infiltrate
- Lipomatous Hypertrophy of the Inter-Atrial Septum
- Elastofibroma Dorsi
- Site of Prior Chest Port
- Esophagitis vs. Neoplasm
- Subcutaneous & Intramuscular Medical Injections
- Injected FDG-Blood Clot
4. Abdomen & Pelvis
- The Heterogeneous Liver
- Liver Ablation
- Hypermetabolic Geographic Fatty Infiltration
- Hypermetabolic Hepatic Adenoma
- FDG-Avid Adrenal Gland Algorithm
- Therapy-Induced Splenic Activation
- Peritoneal Carcinomatosis
- Pre-Sacral Soft Tissue After Rectal Surgery
- Gallbladder: Cholecystitis vs. Malignancy
- Inguinal Herniorraphy
- Bladder in Inguinal Canal
- Uterine Fibroid
- Tampon
5. Miscellaneous (continued)
-
Vascular Uptake
- Atherosclerosis
- Vasculitis
- Vascular Grafts
-
Value of NAC PET Images
- Resolving AC Artifacts
- Lung Nodule Identification
-
Non-Malignant, Yet Clinically Significant, FDG-Avid CT Abnormalies
- Acute Diverticulitis
- Colitis
- Cholecystitis
- Pneumonia
- Abscess
- Pancreatitis
- Skeletal Abnormalities [See Chapter 7]
Chapter 7: The Bones
"...is connected to the..."
Chapter 8: The Cancers
"Putting it all together"
Benign Bone Lesions
Although malignant bone tumors generally have greater FDG uptake than benign lesions, there are simply too many hypermetabolic benign bone lesions to make PET/CT very useful as an indicator of malignancy or benignity.
False Positives: Many benign lesion often demonstrate moderate to intense metabolic activity, including fibrous dysplasia, non-ossifying fibroma, giant cell tumor, aneurysmal bone cyst, Paget’s disease, enchondroma, osteomyelitis, bone infarct and chondroblastoma.
False Negatives: Several malignant bone lesions often demonstrate little or no activity, including low-grade chondrosarcoma, plasmacytoma and myxoid tumors.
Attempting to use PET/CT to distinguish malignant from benign lesions is simply unreliable.
Vertebral Body Hemangioma:
Vertebral body hemangiomas are regularly seen on PET/CT scans and are non-avid.
On CT images, they classically demonstrate a “striated” appearance on sagittal images and a “stippled” appearance on axial images.
While the CT appearance alone is usually diagnostic for hemangiomas, there are cases when it is reassuring to confirm the diagnosis by an absence of metabolic activity on the PET portion of the exam (particularly for those cases where a prior MRI has been equivocal, suggesting the possibility of an “atypical hemangioma”).
Schmorl’s Node:
A Schmorl’s node is a focal herniation of disc material into a vertebral body. It appears as a rounded lucency in the vertebral body, contiguous with its endplate. The lucency often demonstrates surrounding sclerosis.
While typically non-avid, Schmorl’s nodes can be FDG-avid, occasionally demonstrating even intense metabolic activity. MRI evaluation may occasionally be required to distinguish a hypermetabolic Schmorl’s node from a lytic metastasis.
Primary Malignant Bone Tumors:
The role of PET/CT for patients with primary malignant bone tumors is addressed in detail, here.












